Relmada Therapeutics (RLMD) Cash & Equivalents (2012 - 2026)
Relmada Therapeutics (RLMD) reported Cash & Equivalents of $9.8 million for Q1 2026, up 750.34% year-over-year from $1.1 million in Q1 2025, and up 179.6% on a QoQ basis from $3.5 million in Q4 2025.
Relmada Therapeutics (RLMD) has 15 years of Cash & Equivalents data on file, last reported at $9.8 million in Q1 2026.
- Quarterly Cash & Equivalents rose 750.34% year-over-year to $9.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.8 million (up 750.34% YoY) and the FY2025 annual result came in at $3.5 million, down 9.35% from the prior year.
- Cash & Equivalents advanced to $9.8 million in Q1 2026 per RLMD's latest filing, from $3.5 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $44.9 million in Q1 2022 and bottomed at $1.1 million in Q1 2025.
- The 5-year median for Cash & Equivalents is $4.1 million (2023), against an average of $12.4 million.
- The widest annual swing landed in 2022, when Cash & Equivalents surged 1081.23%; it then plunged 95.38% in 2024.
- Tracing RLMD's Cash & Equivalents over 5 years: stood at $5.4 million in 2022, then dropped by 24.17% to $4.1 million in 2023, then slipped by 5.73% to $3.9 million in 2024, then declined by 9.35% to $3.5 million in 2025, then soared by 179.6% to $9.8 million in 2026.
- Per Business Quant, the three latest RLMD Cash & Equivalents figures stand at $9.8 million (Q1 2026), $3.5 million (Q4 2025), and $1.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | 9.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.78 Mn |
| Dec 31, 2025 | 3.50 Mn |
| Sep 30, 2025 | 1.38 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | 3.86 Mn |
| Sep 30, 2024 | 1.48 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Mar 31, 2024 | 1.34 Mn |
| Dec 31, 2023 | 4.09 Mn |
| Sep 30, 2023 | 6.70 Mn |
| Jun 30, 2023 | 14.47 Mn |
| Mar 31, 2023 | 28.89 Mn |
| Dec 31, 2022 | 5.40 Mn |
| Sep 30, 2022 | 42.52 Mn |
| Jun 30, 2022 | 37.26 Mn |
| Mar 31, 2022 | 44.93 Mn |
| Dec 31, 2021 | 44.44 Mn |
| Sep 30, 2021 | 11.45 Mn |
| Jun 30, 2021 | 4.67 Mn |
| Mar 31, 2021 | 3.80 Mn |
| Dec 31, 2020 | 2.50 Mn |
| Sep 30, 2020 | 7.54 Mn |
| Jun 30, 2020 | 13.82 Mn |
| Mar 31, 2020 | 12.23 Mn |
| Dec 31, 2019 | 36.28 Mn |
| Sep 30, 2019 | 7.85 Mn |
| Jun 30, 2019 | 9.22 Mn |
| Mar 31, 2019 | 2.05 Mn |
| Dec 31, 2018 | 2.43 Mn |
| Sep 30, 2018 | 887,494.00 |
| Jun 30, 2018 | 2.24 Mn |
| Mar 31, 2018 | 4.26 Mn |
| Dec 31, 2017 | 5.94 Mn |
| Sep 30, 2017 | 4.68 Mn |
| Jun 30, 2017 | 1.71 Mn |
| Mar 31, 2017 | 2.76 Mn |
| Dec 31, 2016 | 4.71 Mn |
| Sep 30, 2016 | 6.22 Mn |
| Jun 30, 2016 | 8.50 Mn |
| Mar 31, 2016 | 11.35 Mn |
| Dec 31, 2015 | 15.13 Mn |
| Sep 30, 2015 | 19.17 Mn |
| Jun 30, 2015 | 22.47 Mn |
| Mar 31, 2015 | 26.96 Mn |
| Dec 31, 2014 | 31.42 Mn |
| Sep 30, 2014 | 27.39 Mn |
| Jun 30, 2014 | 25.56 Mn |
| Mar 31, 2014 | 2.46 Mn |
| Nov 30, 2013 | 6,166.00 |
| Aug 31, 2013 | 15,290.00 |
| Feb 28, 2013 | 7,504.00 |
| Nov 30, 2012 | 10,446.00 |
| Aug 31, 2012 | 8,949.00 |